Matthias Riemenschneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthias Riemenschneider has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alexander Kurz
Technische Universität München
2 shared publications- Hans Förstl
Institut für Geschichte und Ethik der Medizin, TU München, München, Deutschland
2 shared publications - Simon M. Laws
School of Diagnostic and Therapeutic Sciences, Curtin University, Kent Street, Bentley, WA, 6102, Australia
2 shared publications Andreas Schoepfer-Wendels
Technische Universität München
1 shared publicationAxel Schumacher
Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry, TU-Munich, Germany
1 shared publicationBernd Ibach
University of Regensburg
1 shared publication
Latest Publications
- 28 February 2009
- Published by Elsevier in Neurobiology of Aging
- Vol. 30 (2) , 333-335
No association of common VCP variants with sporadic frontotemporal dementia
- 28 February 2009
- Published by Elsevier in Neurobiology of Aging
- Vol. 30 (2) , 333-335
No association of common VCP variants with sporadic frontotemporal dementia
- 13 May 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 26 (1) , 29-35
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels
Alzheimer disease (AD), vascular dementia, and stroke are all associated with inflammation though their respective initiating factors differ. Recently a polymorphism in the proinflammatory cytokine tumor necrosis factor (TNF), in association with apolipoprotein E (APOE), was reported to increase AD risk. Two SNPs, rs1799724 (–850C>T; NT_007592.14:g.22400733C>T) and rs1800629 (–308G>A; [NT_007592.14:g.22401282G>A]), and the APOE polymorphism were genotyped in 506 patients with sporadic AD and in 277 cognitively healthy controls. In a subset of 90 individuals we also investigated whether these SNPs exerted any functional effects on cerebrospinal fluid (CSF) beta‐amyloid (Aβ) levels. The frequency of the rs1799724 genotypes and the rs1799724‐T allele were significantly different in AD individuals (P=0.009; odds ratio [OR], 1.63; 95% confidence interval [CI], 1.13–2.34), while the rs1800629 SNP was not associated with AD. Significant interaction was observed between the rs1799724‐T and APOE ϵ4 alleles in that the rs1799724‐T allele significantly modified risk associated with possession of the ϵ4 allele only (ϵ4 in absence of rs1799724‐T: OR, 2.92; 95% CI, 2.00–4.27; ϵ4 in presence of rs1799724‐T: OR, 6.65; 95% CI, 3.26–13.55; P=0.03). Haplotyping analysis revealed a significant overrepresentation of an rs1799724‐T/rs1800629‐G haplotype in AD (P=0.012; OR, 1.60; 95% CI, 1.11–2.29), although to a lesser degree than rs1799724‐T alone. Further, the rs1799724‐T allele was found to be associated with lower levels of CSF Aβ42 (P=0.023), thus corroborating the genetic findings. Inheritance of the rs1799724‐T allele appears to synergistically increase the risk of AD in APOEϵ4 carriers and is associated with altered CSF Aβ42 levels. Further investigations are warranted to assess the significance of these novel findings. Hum Mutat 26(1), 29–35, 2005.
- 13 May 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 26 (1) , 29-35
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels
Alzheimer disease (AD), vascular dementia, and stroke are all associated with inflammation though their respective initiating factors differ. Recently a polymorphism in the proinflammatory cytokine tumor necrosis factor (TNF), in association with apolipoprotein E (APOE), was reported to increase AD risk. Two SNPs, rs1799724 (–850C>T; NT_007592.14:g.22400733C>T) and rs1800629 (–308G>A; [NT_007592.14:g.22401282G>A]), and the APOE polymorphism were genotyped in 506 patients with sporadic AD and in 277 cognitively healthy controls. In a subset of 90 individuals we also investigated whether these SNPs exerted any functional effects on cerebrospinal fluid (CSF) beta‐amyloid (Aβ) levels. The frequency of the rs1799724 genotypes and the rs1799724‐T allele were significantly different in AD individuals (P=0.009; odds ratio [OR], 1.63; 95% confidence interval [CI], 1.13–2.34), while the rs1800629 SNP was not associated with AD. Significant interaction was observed between the rs1799724‐T and APOE ϵ4 alleles in that the rs1799724‐T allele significantly modified risk associated with possession of the ϵ4 allele only (ϵ4 in absence of rs1799724‐T: OR, 2.92; 95% CI, 2.00–4.27; ϵ4 in presence of rs1799724‐T: OR, 6.65; 95% CI, 3.26–13.55; P=0.03). Haplotyping analysis revealed a significant overrepresentation of an rs1799724‐T/rs1800629‐G haplotype in AD (P=0.012; OR, 1.60; 95% CI, 1.11–2.29), although to a lesser degree than rs1799724‐T alone. Further, the rs1799724‐T allele was found to be associated with lower levels of CSF Aβ42 (P=0.023), thus corroborating the genetic findings. Inheritance of the rs1799724‐T allele appears to synergistically increase the risk of AD in APOEϵ4 carriers and is associated with altered CSF Aβ42 levels. Further investigations are warranted to assess the significance of these novel findings. Hum Mutat 26(1), 29–35, 2005.